Prochlorperazine-Induced Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome (NMS) is an uncommon but potentially fatal neurological emergency associated most often with dopamine-receptor-blocking drugs. The reference report, Prochlorperazine-induced neuroleptic malignant syndrome, is clinically valuable because it describes NMS after prochlorperazine prescribed for peripheral-vertigo-related nausea rather than for a primary psychiatric disorder. The case also challenges an overly laboratory-dependent approach: the patient developed the characteristic clinical syndrome despite only modest creatine phosphokinase elevation and a normal white blood cell count.

Study Background and Research Question

NMS is classically recognized through the combination of hyperthermia, altered mental status, generalized rigidity, and autonomic instability. Its pathophysiology is generally linked to central dopamine blockade involving thermoregulatory and motor-control circuits in the hypothalamus and brainstem. However, the syndrome can resemble serotonin syndrome, central nervous system infection, malignant hyperthermia, malignant catatonia, or other drug-related emergencies. This overlap makes the medication history and temporal progression especially important.

The report asks a practical emergency-medicine question: can prochlorperazine at a conventional prescribed dose precipitate NMS in an older patient without the striking laboratory abnormalities commonly associated with the syndrome? The patient was a 76-year-old man with hypertension, type 2 diabetes, and chronic atrial fibrillation. He had taken prochlorperazine 5 mg twice daily for approximately two weeks before presenting with two days of fever and acute mental-status change. According to the reference study, no other newly introduced medication was identified during that interval.

Key Innovation from the Reference Study

The main innovation is diagnostic rather than technological: the report demonstrates that NMS should remain a clinical diagnosis even when supportive laboratory findings are limited. On admission, the patient had fever above 38 °C, tachycardia, a respiratory rate above 30 breaths per minute, labile blood pressure, drowsiness, reduced motor activity, tremor, and generalized lead-pipe rigidity. His Glasgow Coma Scale score was 12, indicating moderate impairment.

In contrast, the initial creatine phosphokinase concentration was only 256 U/L and later peaked at 454 U/L. The white blood cell count, electrolytes, blood ammonia, and blood-gas analysis were not suggestive of a major alternative metabolic process. This pattern is important because clinicians may incorrectly exclude NMS when creatine phosphokinase is not dramatically elevated. The report therefore adds a cautionary example to the emergency-neurology literature: clinical progression and exposure history can be more informative than any isolated biomarker.

A second contribution is the focus on prochlorperazine, a phenothiazine antiemetic that may be perceived as less concerning than antipsychotics prescribed at higher doses. The case shows that dopamine antagonism remains clinically relevant when the drug is used for a nonpsychiatric indication and at a standard regimen. It also illustrates the importance of considering adverse drug reactions in patients with multiple chronic diseases, whose baseline symptoms and medication lists can complicate interpretation.

Methods and Experimental Design Insights

This was a detailed single-patient case report rather than a controlled trial. Its methodology consisted of chronological clinical documentation: prior diseases and medication exposure, presenting symptoms, neurological examination, laboratory testing, imaging, cerebrospinal-fluid analysis, electroencephalography, treatment, and follow-up. That design cannot estimate incidence or establish comparative treatment efficacy, but it is well suited to recognizing an unusual adverse-drug presentation.

The initial evaluation addressed several competing explanations for fever and impaired consciousness. Brain computed tomography showed no acute intracranial abnormality. Lumbar puncture revealed mildly elevated cerebrospinal-fluid protein with otherwise unremarkable findings. Electroencephalography later showed no epileptiform discharges. The neurological examination was also informative: generalized rigidity and tremor were accompanied by reduced deep-tendon reflexes and negative Babinski signs. The absence of serotonergic co-medication and the lack of the hyperreflexia or clonus typically associated with serotonin toxicity supported NMS over serotonin syndrome.

Protocol Parameters

• Exposure assessment: Review all prescription and nonprescription drugs, with particular attention to dopamine antagonists introduced during the preceding days or weeks.
• Clinical trigger: Evaluate fever, altered consciousness, autonomic instability, tremor, and generalized rigidity together rather than using creatine phosphokinase concentration as a standalone screening criterion.
• Case laboratory profile: The reported creatine phosphokinase was 256 U/L initially and 454 U/L at its peak; these values belong to the case description and should not be interpreted as universal diagnostic thresholds.
• Diagnostic exclusion: Use brain imaging, cerebrospinal-fluid examination, electroencephalography, and targeted laboratory testing when the presentation requires exclusion of intracranial disease, infection, seizure, or metabolic causes.
• Therapeutic approach in the report: The patient received intravenous lorazepam 1 mg every six hours and oral amantadine 100 mg every 12 hours after prochlorperazine was stopped. These are reported case-management parameters, not a substitute for institution-specific emergency protocols.
• Follow-up: Monitor temperature, consciousness, rigidity, autonomic function, and medication tolerance during recovery; in this case, amantadine was later discontinued after outpatient assessment showed no recurrent mental-status change or rigidity.

The practical lesson is to structure evaluation around syndrome recognition and exclusion of dangerous mimics. The report does not test whether one treatment is superior to another, so its medication details should be interpreted as an observed management pathway rather than as comparative evidence.

Core Findings and Why They Matter

After treatment with lorazepam and amantadine, the patient improved progressively. Fever resolved, consciousness returned to a Glasgow Coma Scale score of 15, and generalized rigidity disappeared. Lorazepam was tapered, and the patient was discharged while continuing oral amantadine. Subsequent outpatient follow-up was unremarkable, allowing amantadine to be stopped. These outcomes support the report’s central message that early recognition and prompt pharmacological management can be followed by recovery, even when the initial laboratory profile is not dramatic.

The case also demonstrates why medication history must be integrated with examination findings. Prochlorperazine had been prescribed for nausea associated with peripheral vertigo, and the patient had no obvious alternative drug trigger. The temporal relationship, classic motor findings, autonomic disturbance, and exclusion of major competing diagnoses together provided a stronger diagnostic basis than the modest enzyme elevation alone.

For researchers, the report identifies several clinically relevant variables for future case series and pharmacovigilance studies: age, comorbidity burden, indication for prochlorperazine, cumulative exposure, time to symptom onset, neuromuscular signs, laboratory severity, treatment timing, and recurrence during follow-up. Systematic collection of these features could help clarify whether older adults with cardiovascular or metabolic disease have distinct presentation or recovery patterns.

Comparison with Existing Internal Articles

The available internal resources approach experimental research from a different direction. The scenario-driven assay resource emphasizes cell-viability, cytotoxicity, and neurodegenerative-disease workflows, while the mitochondrial-modulation resource focuses on biochemical mechanisms and probe applications. Those articles are useful for planning laboratory assays, but they do not provide clinical evidence about prochlorperazine exposure, NMS diagnosis, or emergency treatment.

In comparison, the reference case is centered on bedside phenotyping and longitudinal observation rather than molecular intervention. The relationship is therefore methodological: both types of resource emphasize careful characterization and reproducibility, but their endpoints differ. In vitro assay readouts cannot be used to infer that a compound prevents or treats NMS, and a single clinical case cannot validate a laboratory mechanism.

Limitations and Transferability

The most important limitation is the single-patient design. A case report can reveal a clinically important association but cannot determine how frequently prochlorperazine causes NMS, identify independent risk factors, or compare lorazepam and amantadine with alternative treatments. The patient’s age and comorbidities may also limit direct transferability to younger adults or individuals without chronic cardiovascular and metabolic disease.

Diagnostic uncertainty cannot be eliminated entirely in a retrospective clinical narrative. Although imaging, cerebrospinal-fluid testing, electroencephalography, examination findings, and medication history supported NMS, no single test confirms the diagnosis. Creatine phosphokinase can vary with timing, muscle injury, hydration, and disease severity; therefore, the relatively low values in this patient should not be generalized as typical for all prochlorperazine-associated cases.

Why this cross-domain matters, maturity, and limitations

Connecting this emergency-neurology case with biochemical or flavonoid research requires caution. The reference study supports clinical recognition and management of a drug-induced neurological emergency; it does not establish a role for antioxidant, anti-inflammatory, mitochondrial, or metal-chelating compounds in NMS. Laboratory studies may help investigate oxidative stress or neuronal signaling in other disease models, but such findings remain mechanistically separate from treatment evidence for prochlorperazine-induced NMS.

Accordingly, the mature conclusion is narrow but useful: clinicians should maintain suspicion for NMS after dopamine-antagonist exposure, even at standard doses and without marked laboratory abnormalities. Transfer to other drugs, patient populations, or experimental interventions requires independent pharmacological and clinical evidence.

Research Support Resources

For researchers building adjacent biochemical workflows, Morin (SKU C5297), chemically identified as 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one and also known as Morin CAS 480-16-0, can support laboratory studies distinct from NMS treatment. The product information describes uses involving Morin antioxidant activity, an anti-inflammatory flavonoid for diabetes research, a fluorescent aluminum ion probe, inhibition of adenosine 5′-monophosphate deaminase, and evaluation as a cardioprotective and neuroprotective agent. These applications should remain within appropriately validated experimental models and should not be interpreted as evidence for managing prochlorperazine-induced NMS.